false 2022-06-30 2022 Q2 0001809196--12-31 0001809196 2022-06-30 0001809196 2021-12-31 0001809196 2021-01-01 2021-06-30 0001809196 2022-04-01 2022-06-30 0001809196 2021-04-01 2021-06-30 0001809196 2022-01-01 2022-06-30 0001809196 2021-06-30 0001809196 2020-12-31 0001809196 ifrs-full:OtherReservesMember 2022-01-01 2022-06-30 0001809196 ifrs-full:RetainedEarningsMember 2022-01-01 2022-06-30 0001809196 ifrs-full:SharePremiumMember 2022-01-01 2022-06-30 0001809196 imtx:CelgeneSwitzerlandLlcAndGenmabAsMember 2022-01-01 2022-06-30 0001809196 imtx:NonInterestBearingLiabilityMember 2022-01-01 2022-06-30 0001809196 imtx:AdditionalGrantsUnderTwoThousandAndTwentyPlanMember 2022-01-01 2022-06-30 0001809196 imtx:PerformanceBasedOptionsMember 2022-01-01 2022-06-30 0001809196 imtx:MatchingStockOptionsMember 2022-01-01 2022-06-30 0001809196 imtx:ConvertedOptionsMember 2022-01-01 2022-06-30 0001809196 imtx:AdditionalGrantsUnderTwoThousandAndTwentyPlanMember imtx:GrantedOnMarchTwoThousandAndTwentyTwoMember 2022-01-01 2022-06-30 0001809196 imtx:GrantedInJuneTwoThousandAndTwentyTwoMember imtx:AdditionalGrantsUnderTwoThousandAndTwentyPlanMember 2022-01-01 2022-06-30 0001809196 imtx:GrantedInJuneTwoThousandAndTwentyTwoMember imtx:ConvertedOptionsMember 2022-01-01 2022-06-30 0001809196 imtx:MatchingStockOptionsMember 2022-01-01 2022-06-30 0001809196 imtx:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-06-30 0001809196 imtx:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-06-30 0001809196 ifrs-full:IssuedCapitalMember 2022-01-01 2022-06-30 0001809196 imtx:BMSCollaborationAgreementMember imtx:Ima401Member 2022-01-01 2022-06-30 0001809196 imtx:SvbSecuritiesLlcMember imtx:AtTheMarketAgreementMember 2022-01-01 2022-06-30 0001809196 imtx:WarrantsMember imtx:AryaMember 2022-01-01 2022-06-30 0001809196 imtx:RentalLandMember 2022-01-01 2022-06-30 0001809196 imtx:CollaborationAgreementsMember 2022-01-01 2022-06-30 0001809196 imtx:GSKCollaborationAgreementMember 2022-01-01 2022-06-30 0001809196 imtx:BMSCollaborationAgreementMember 2022-01-01 2022-06-30 0001809196 imtx:GenmabCollaborationAgreementMember 2022-01-01 2022-06-30 0001809196 imtx:AmgenCollaborationAgreementMember 2022-01-01 2022-06-30 0001809196 imtx:KeyManagementPersonnelAndBoardOfDirectorsMember imtx:ServiceOptionsMember 2022-01-01 2022-06-30 0001809196 imtx:Ima401LicenseGrantMember imtx:ImmaticsBiotechnologiesGmbhMember imtx:BmsAgreementMember 2022-01-01 2022-06-30 0001809196 imtx:ImmaticsBiotechnologiesGmbhMember imtx:Ima401ClinicalTrialServicesMember imtx:BmsAgreementMember 2022-01-01 2022-06-30 0001809196 imtx:ReceivablesFromCapitalGainsTaxMember 2022-06-30 0001809196 imtx:CelgeneSwitzerlandLlcAndGenmabAsMember 2022-06-30 0001809196 imtx:OtherCurrentAndNonCurrentAssetsMember imtx:OtherFinancialAssetsAtAmortizedCostMember 2022-06-30 0001809196 ifrs-full:TradeReceivablesMember imtx:OtherFinancialAssetsAtAmortizedCostMember 2022-06-30 0001809196 imtx:BondsMember imtx:OtherFinancialAssetsAtAmortizedCostMember 2022-06-30 0001809196 imtx:AccountsPayableMember imtx:OtherFinancialAssetsAtAmortizedCostMember 2022-06-30 0001809196 imtx:OtherCurrentLiabilitiesMember imtx:OtherFinancialAssetsAtAmortizedCostMember 2022-06-30 0001809196 ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember imtx:OtherFinancialLiabilitiesMember 2022-06-30 0001809196 imtx:MatchingStockOptionsMember 2022-06-30 0001809196 imtx:ConvertedOptionsMember 2022-06-30 0001809196 imtx:AdditionalGrantsUnderTwoThousandAndTwentyPlanMember 2022-06-30 0001809196 imtx:PerformanceBasedOptionsMember 2022-06-30 0001809196 imtx:TrancheOneMember imtx:PerformanceBasedOptionsMember 2022-06-30 0001809196 imtx:TrancheTwoMember imtx:PerformanceBasedOptionsMember 2022-06-30 0001809196 imtx:TrancheThreeMember imtx:PerformanceBasedOptionsMember 2022-06-30 0001809196 imtx:ImmaticsBiotechnologiesGmbhMember country:DE 2022-06-30 0001809196 imtx:BristolMyerSquibCompanyMember imtx:ImmaticsUsIncMember imtx:LicenseDevelopmentAndCommercializationAgreementMember 2022-06-30 0001809196 imtx:BristolMyerSquibCompanyMember imtx:ImmaticsBiotechnologiesGmbhMember imtx:AmendmentToTheStrategicCollaborationAgreementMember 2022-06-30 0001809196 imtx:CollaborationAgreementMember 2022-06-30 0001809196 ifrs-full:TopOfRangeMember 2022-06-30 0001809196 imtx:ReceivablesFromLeaseIncentiveMember 2022-06-30 0001809196 imtx:BmsAgreementMember 2022-06-30 0001809196 imtx:ReceivablesFromCapitalGainsTaxMember 2021-12-31 0001809196 imtx:OtherCurrentAndNonCurrentAssetsMember imtx:OtherFinancialAssetsAtAmortizedCostMember 2021-12-31 0001809196 ifrs-full:TradeReceivablesMember imtx:OtherFinancialAssetsAtAmortizedCostMember 2021-12-31 0001809196 imtx:BondsMember imtx:OtherFinancialAssetsAtAmortizedCostMember 2021-12-31 0001809196 imtx:AccountsPayableMember imtx:OtherFinancialAssetsAtAmortizedCostMember 2021-12-31 0001809196 imtx:OtherCurrentLiabilitiesMember imtx:OtherFinancialAssetsAtAmortizedCostMember 2021-12-31 0001809196 ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember imtx:OtherFinancialLiabilitiesMember 2021-12-31 0001809196 imtx:ResearchAndDevelopmentExpenseMember 2022-04-01 2022-06-30 0001809196 imtx:GeneralAndAdministrativeExpenseMember 2022-04-01 2022-06-30 0001809196 imtx:AtTheMarketAgreementMember imtx:SvbSecuritiesLlcMember 2022-04-01 2022-06-30 0001809196 imtx:WarrantsMember imtx:AryaMember 2022-04-01 2022-06-30 0001809196 imtx:CollaborationAgreementsMember 2022-04-01 2022-06-30 0001809196 imtx:GSKCollaborationAgreementMember 2022-04-01 2022-06-30 0001809196 imtx:BMSCollaborationAgreementMember 2022-04-01 2022-06-30 0001809196 imtx:GenmabCollaborationAgreementMember 2022-04-01 2022-06-30 0001809196 imtx:AmgenCollaborationAgreementMember 2022-04-01 2022-06-30 0001809196 country:DE imtx:ImmaticsBiotechnologiesGmbhMember 2022-04-01 2022-06-30 0001809196 imtx:AmendmentToTheStrategicCollaborationAgreementMember imtx:ImmaticsBiotechnologiesGmbhMember imtx:BristolMyerSquibCompanyMember 2022-04-01 2022-06-30 0001809196 imtx:BristolMyerSquibCompanyMember imtx:ImmaticsUsIncMember imtx:LicenseDevelopmentAndCommercializationAgreementMember 2022-04-01 2022-06-30 0001809196 imtx:ImmaticsBiotechnologiesGmbhMember imtx:Ima401ClinicalTrialServicesMember imtx:BmsAgreementMember 2022-04-01 2022-06-30 0001809196 imtx:ResearchAndDevelopmentExpenseMember 2021-04-01 2021-06-30 0001809196 imtx:GeneralAndAdministrativeExpenseMember 2021-04-01 2021-06-30 0001809196 imtx:CollaborationAgreementsMember 2021-04-01 2021-06-30 0001809196 imtx:GSKCollaborationAgreementMember 2021-04-01 2021-06-30 0001809196 imtx:BMSCollaborationAgreementMember 2021-04-01 2021-06-30 0001809196 imtx:GenmabCollaborationAgreementMember 2021-04-01 2021-06-30 0001809196 imtx:AmgenCollaborationAgreementMember 2021-04-01 2021-06-30 0001809196 ifrs-full:OtherReservesMember 2021-01-01 2021-06-30 0001809196 ifrs-full:RetainedEarningsMember 2021-01-01 2021-06-30 0001809196 ifrs-full:SharePremiumMember 2021-01-01 2021-06-30 0001809196 imtx:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-06-30 0001809196 imtx:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-06-30 0001809196 imtx:CollaborationAgreementsMember 2021-01-01 2021-06-30 0001809196 imtx:GSKCollaborationAgreementMember 2021-01-01 2021-06-30 0001809196 imtx:BMSCollaborationAgreementMember 2021-01-01 2021-06-30 0001809196 imtx:GenmabCollaborationAgreementMember 2021-01-01 2021-06-30 0001809196 imtx:AmgenCollaborationAgreementMember 2021-01-01 2021-06-30 0001809196 imtx:CelgeneSwitzerlandLlcAndGenmabAsMember 2021-01-01 2021-12-31 0001809196 imtx:AdditionalGrantsUnderTwoThousandAndTwentyPlanMember 2022-03-22 2022-03-22 0001809196 imtx:AdditionalGrantsUnderTwoThousandAndTwentyPlanMember imtx:GrantedOnMarchTwoThousandAndTwentyTwoMember 2022-03-22 2022-03-22 0001809196 imtx:AdditionalGrantsUnderTwoThousandAndTwentyPlanMember 2022-03-29 2022-03-29 0001809196 imtx:AdditionalGrantsUnderTwoThousandAndTwentyPlanMember imtx:GrantedOnMarchTwoThousandAndTwentyTwoMember 2022-03-29 2022-03-29 0001809196 imtx:AdditionalGrantsUnderTwoThousandAndTwentyPlanMember 2022-06-14 2022-06-14 0001809196 imtx:AdditionalGrantsUnderTwoThousandAndTwentyPlanMember imtx:GrantedInJuneTwoThousandAndTwentyTwoMember 2022-06-14 2022-06-14 0001809196 imtx:AdditionalGrantsUnderTwoThousandAndTwentyPlanMember 2022-06-30 2022-06-30 0001809196 imtx:AdditionalGrantsUnderTwoThousandAndTwentyPlanMember imtx:GrantedInJuneTwoThousandAndTwentyTwoMember 2022-06-30 2022-06-30 0001809196 ifrs-full:BottomOfRangeMember 2022-03-31 0001809196 imtx:BmsAgreementMember imtx:ImmaticsBiotechnologiesGmbhMember 2022-03-31 0001809196 imtx:IssueOfSecuritiesMember imtx:SvbSecuritiesLlcMember imtx:AtTheMarketAgreementMember 2022-08-09 0001809196 imtx:AuthorizationOfFinancialStatementsMember 2022-08-09 2022-08-09 0001809196 imtx:AtTheMarketAgreementMember imtx:SvbSecuritiesLlcMember imtx:IssueOfSecuritiesMember 2022-08-09 2022-08-09 0001809196 imtx:BristolMyerSquibCompanyMember imtx:ImmaticsUsIncMember imtx:LicenseDevelopmentAndCommercializationAgreementMember 2022-06-01 2022-06-01 0001809196 imtx:BristolMyerSquibCompanyMember imtx:ImmaticsBiotechnologiesGmbhMember imtx:AmendmentToTheStrategicCollaborationAgreementMember 2022-06-01 2022-06-01 0001809196 imtx:BmsAgreementMember imtx:ImmaticsBiotechnologiesGmbhMember 2022-01-26 2022-01-26 0001809196 imtx:ImmaticsBiotechnologiesGmbhMember 2022-01-26 0001809196 imtx:ImmaticsBiotechnologiesGmbhMember imtx:DevelopmentRegulatoryAndCommercialMilestoneMember imtx:BmsAgreementMember 2022-01-26 0001809196 ifrs-full:OtherReservesMember 2021-12-31 0001809196 ifrs-full:RetainedEarningsMember 2021-12-31 0001809196 ifrs-full:SharePremiumMember 2021-12-31 0001809196 ifrs-full:IssuedCapitalMember 2021-12-31 0001809196 imtx:MatchingStockOptionsMember 2021-12-31 0001809196 imtx:ConvertedOptionsMember 2021-12-31 0001809196 imtx:AdditionalGrantsUnderTwoThousandAndTwentyPlanMember 2021-12-31 0001809196 imtx:PerformanceBasedOptionsMember 2021-12-31 0001809196 ifrs-full:OtherReservesMember 2022-06-30 0001809196 ifrs-full:RetainedEarningsMember 2022-06-30 0001809196 ifrs-full:SharePremiumMember 2022-06-30 0001809196 ifrs-full:IssuedCapitalMember 2022-06-30 0001809196 ifrs-full:IssuedCapitalMember 2020-12-31 0001809196 ifrs-full:SharePremiumMember 2020-12-31 0001809196 ifrs-full:RetainedEarningsMember 2020-12-31 0001809196 ifrs-full:OtherReservesMember 2020-12-31 0001809196 ifrs-full:IssuedCapitalMember 2021-06-30 0001809196 ifrs-full:OtherReservesMember 2021-06-30 0001809196 ifrs-full:RetainedEarningsMember 2021-06-30 0001809196 ifrs-full:SharePremiumMember 2021-06-30 iso4217:EUR xbrli:pure iso4217:USD utr:Year xbrli:shares iso4217:USD xbrli:shares iso4217:EUR xbrli:shares utr:Y
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
6-K
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule
13a-16
or
15d-16
of the Securities Exchange Act of 1934
August 9, 2022
Commission File Number:
001-39363
IMMATICS N.V.
Paul-Ehrlich-Straße 15
72076 Tübingen, Federal Republic of Germany
(Address of Principal Executive Office)
Indicate by check mark whether the registrant files or will file annual reports under cover Form
20-F
or Form
40-F.
Form
20-F ☒
Form
40-F ☐
Indicate by check mark if the registrant is submitting the Form
6-K
in paper as permitted by Regulation
S-T
Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form
6-K
in paper as permitted by Regulation
S-T
Rule 101(b)(7): ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM
6-K
On August 9, 2022, Immatics N.V. (the “Company”) issued an interim report for the three and
six-month
periods ended June 30, 2022, which is attached hereto as Exhibit 99.1, and issued a press release announcing the second quarter 2022 financial results for the Company, which is attached hereto as Exhibit 99.2.
INCORPORATION BY REFERENCE
This Report on Form
6-K
(other than Exhibit 99.2 hereto), including Exhibit 99.1 hereto, shall be deemed to be incorporated by reference into the registration statements on Form
S-8
(333-249408
and
333-265820)
and the registration statements on Form
F-3
(Registration Nos.
333-258351
and
333-240260)
of Immatics N.V. and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
EXHIBITS

Exhibit Number |  | Description
99.1 |  | Immatics N.V. interim report for the three and six-month periods ended June 30, 2022.
99.2 |  | Press release dated August 9, 2022.
101.INS |  | XBRL Taxonomy Extension Instance Document
101.SCH |  | XBRL Taxonomy Extension Schema Document
101.CAL |  | XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF |  | XBRL Taxonomy Extension Definition Linkbase Document
101.LAB |  | XBRL Taxonomy Extension Label Linkbase Document
101.PRE |  | XBRL Taxonomy Extension Presentation Linkbase Document

1

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

|  |  |  | IMMATICS N.V.
Date: August 9, 2022 |  |  |  | by: |  | /s/ Harpreet Singh
|  |  |  |  |  | Harpreet Singh
|  |  |  |  |  | Chief Executive Officer

2